Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with renowned Australian biotech entrepreneur Paul Hopper.

Paul has over 25 years experience in the biotech, healthcare & life sciences sectors, largely with listed companies.

A specialist with start-up and rapid growth companies, Paul has served as either founder, chairman, non-executive director, or CEO of more than 14 companies in the US, Australia and Asia.

Previous and current boards include Viralytics, Imugene, Prescient Therapeutics, Polynoma and Suda Medical.

Paul’s latest venture is Chimeric Therapeutics (ASX:CHM), which jumped 80 per cent on its ASX debut.

Chimeric featured in a recent Stockhead video looking at how CAR T cell therapies are driving better cancer treatment outcomes.

So tune in below to hear about Paul’s entry into the biotech sector, the keys to his success raising capital and his thoughts on what makes a biotech winner.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!